NCT07505095Not yet recruiting
Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 26 Mar 2026
- Start date
- 30 Apr 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Alzheimer disease
- NCT number
- NCT07505095
What you commit to
- Study type: Observational
- Planned participants: 140
- From 30 Apr 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Effects of drugs/toxins: long-term use of benzodiazepines, anticholinergic drugs, or alcohol dependence.
Other illness
- Other neurological disorders: e.g., vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration, prion diseases, etc.
- Systemic diseases or metabolic disorders: e.g., hypothyroidism, vitamin B12 deficiency, hepatic and renal failure.
- Infectious diseases: e.g., neurosyphilis, HIV-associated encephalopathy, and other infectious diseases.
- Psychiatric disorders: cognitive symptoms caused by severe depression (pseudodementia), schizophrenia, etc.
Who the study is looking for
- Meet the diagnostic criteria for AD-derived MCI or early AD \[Clinical rating: CDR 0.5 (MCI) / 1.0 (mild AD), i.e., clinical stage 3-5; PIB-PET positive for pathology\]
- Male or female
- 50-85 years old
- Not currently participating in other research studies
- Volunteers must provide written informed consent prior to study participation and voluntarily sign the informed consent form
- Volunteers are able to communicate effectively with investigators and comply with study procedures to complete the study
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Human Subject Research Ethics Committee, 2ndAffiliated Hospital, School of Medicine, Zhejiang University, Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.